Role of fulvestrant in the management of postmenopausal breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 11, 2011, Pages 1641-1652

  Krell, Jonathan ^a   Januszewski, Adam ^a   Yan, Kelvin ^a   Palmieri, Carlo ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Endocrine therapy; Fulvestrant; Selective estrogen receptor downregulator

Indexed keywords

ANASTROZOLE; EXEMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; PLACEBO; TAMOXIFEN; TOREMIFENE; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG HALF LIFE; DRUG RESISTANCE; ENZYME INHIBITION; HORMONAL THERAPY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MAXIMUM CONCENTRATION; MINIMUM CONCENTRATION; NONHUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TROUGH CONCENTRATION; ANIMAL; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG SCREENING; FEMALE; METABOLISM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN;

EID: 84858719740     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.11.138     Document Type: Article

References (61)

1. Fawell SE, White R, Hoare S et al. Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl Acad. Sci. USA 87, 6883-6887 (1990).
2. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl Acad. Sci. USA 89 4037-4041 (1992).
3. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106(Pt 4), 1377-1388 (1993).
4. Wijayaratne AL, Nagel SC, Paige LA et al. Comparative analyses of mechanistic differences among antioestrogens. Endocrinology. 140, 5828-5840 (1999).
5. Frasor J, Stossi F, Danes JM et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64, 1522-1533 (2004).
6. Hutcheson IR, Knowlden JM, Madden T-A et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 81, 81-93 (2003).
7. Ignar-Trowbridge DM, Teng CT, Ross KA et al. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol. 7, 992-998 (1993).
8. McClelland RA, Gee JM, Francis AB et al. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur. J. Cancer 32A, 413-416 (1996).
9. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor and estrogen receptor in human breast cancer. J. Biol. Chem. 253, 2223-2238 (1978).
10. Nicholson RI, Gee JM, Francis AB et al. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growthindependent (K3) human breast cancer cells. Endocr. Relat. Cancer 2, 115-121 (1995).
11. Nicholson RI, Gee JM, Manning DL et al. Responses to pure antiestrogens (ICI 164,384, ICI 182,780) in estrogensensitive and -resistant experimental and clinical breast cancer. Ann. NY Acad. Sci. 761, 148-163 (1995).
12. Dos Santos EG, Dieudonne MN, Pecquery R et al. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology. 143, 930-940 (2002).
13. Wakeling A. E., Bowler J. Steroidal pure antioestrogens. J. Endocrinol. 112, R7-R10 (1987).
14. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867-3873 (1991).
15. Hu XF, Veroni M, De Luise M et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873-876 (1993).
16. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54, 1587-1595 (1994).
17. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer 61, 529-534 (1995).
18. Brünner N, Boysen B, Jirus S et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57, 3486-3493 (1997).
19. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl Cancer Inst. 87, 746-750 (1995).
20. Harrison M, Laight A, Clarke DA et al Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. Proc. ASCO 22, 45 (2003) (Abstract 311).
21. Robertson JF, Erikstein B, Osborne KC et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin. Pharmacokinet. 43, 529-538 (2004).
22. Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolongedrelease fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother. Pharmacol. 52(4), 346-348 (2003).
23. Dukes M, Waterton JC, Wakeling AE. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J. Endocrinol. 138(2), 203-210 (1993).
24. Thomas EJ, Walton PL, Thomas NM, Dowsett M. The effects of fulvestrant, a pure anti-estrogen, on the hypothalamic- pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum. Reprod. 9, 1991-1996 (1994).
25. Addo S, Yates RA, Laight A. A Phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer. 87, 1354-1359 (2002).
26. Donnez J, Hervais Vivancos B, Kudela M et al. A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil. Steril. 79(6), 1380-1389 (2003).
27. Bross PF, Baird A, Chen G et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin. Cancer Res. 9, 430 (2003).
28. DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 54, 408-414 (1994).
29. Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biological effects of 7α-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl] estra-1,3,5,(10)-triene-3,17β-diol (FVT) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 18, 6739-6746 (2001).
30. Robertson JFR, Gutteridge E, Cheung KL et al. Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment. Proc. Am. Soc. Clin. Oncol. 11 (2004) (Abstract 536).
31. Howell A, DeFriend DJ, Robertson JF et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345(8941), 29-30 (1995).
32. Robertson JR, Howell A, DeFriend DJ et al. Duration of remission to ICI 182780 compared to megestrol acetate in tamoxifen resistant breast cancer. Breast 6(4), 186-189 (1997).
33. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20, 3396-3403 (2002).
34. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 20, 3386-3395 (2002).
35. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98, 229-238 (2003).
36. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104(2), 236-239 (2005).
37. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 22, 1605-1613 (2004).
38. Ingle J, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J. Clin. Oncol. 24, 1052-1056 (2006).
39. Perey L, Paridaens R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 18(1), 64-69 (2007).
40. Evans TR, Di Salle E, Ornati G et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 52, 5933-5939 (1992).
41. Lønning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J. Clin. Oncol. 18, 2234-2244 (2000).
42. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J. Clin. Oncol. 26, 1664-1670 (2008).
43. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res. Treat. 117(1), 69-75 (2009).
44. Bergh J, Jonsson PE, Lidbrink E et al. First Results from FACT - an open-label, randomized Phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2009 (Abstract 23).
45. Robertson JF, Llombart-Cussac K, Rolski K et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results From the FIRST Study. J. Clin. Oncol. 27(27), 4530-4535 (2009).
46. Kuter I, Hegg R, Singer CF et al. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, Phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res. Treat. 106 (2007) (Abstract 589).
47. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 28, 4594-4600 (2010).
48. Ohno S, Rai Y, Iwata H et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, Phase II comparative study (FINDER1). Ann. Oncol. 21(12), 2342-2347 (2010).
49. Pritchard K, Rolski J, Pápai Z et al. A Phase II study (FINDER 2) comparing three dosing regimens of fulvestrant in postmenopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer Res. Treat. 123(2), 453-461 (2010).
50. Young OE, Renshaw L, Macaskill EJ et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogenreceptor- positive primary breast cancer. Eur. J. Cancer 44, 391-399 (2008).
51. Masamura S, Santner SJ, Heitjan DF et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80(10), 2918-2925 (1995).
52. Santen R, Jeng MH, Wang JP et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J. Steroid Biochem. Mol. Biol. 79(1-5), 115-125 (2001).
53. Chan CM, Martin LA, Johnston SR et al. Molecular changes associated with acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81(4-5), 333-341 (2002).
54. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in longterm estrogen-deprived human breast cancer cells. Endocrinology 139 (10), 4164-4174 (1998).
55. Jelovac D, Macedo L, Goloubeva OG et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 65, 5439-5444 (2005).
56. Macedo LF, Sabnis GJ, Goloubeva OG et al. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 68, 3516-3522 (2008).
57. Long BJ, Jelovac D, Handratta V et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J. Natl Cancer Inst. 96, 456-465 (2004).
58. Long BJ, Jelovac D, Thiantanawat A, Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res. 8, 2378-2388 (2002).
59. Robertson JF, Steger GG, Neven P et al. Activity of fulvestrant in HER2- overexpressing advanced breast cancer. Ann. Oncol. 21, 1246-1253 (2010).
60. Palmieri C, Januszewski A, Stanway S, Coombes RC. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev. Anticancer Ther. 11(2), 179-183 (2011).
61. Barrie SE, Potter GA, Goddard PM et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) α (17 α-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50, 267-273 (1994).